MedPath

Mifepristone Versus Osmotic Dilator Insertion for Cervical Preparation Prior to Surgical Abortion at 15-18 Weeks

Phase 3
Completed
Conditions
Cervical Preparation
Interventions
Device: osmotic dilators
Registration Number
NCT01436279
Lead Sponsor
Boston University
Brief Summary

In this study the investigators plan to compare mifepristone and misoprostol use to osmotic dilator use for cervical preparation for 15-18 week surgical abortion. Mifepristone would be given 24 hours prior to abortion, and misoprostol 400 mcg would be administered buccally 2 hours prior to abortion. Osmotic dilators are the method currently used in our institution, and are placed 24 hours prior to abortion. The primary outcome will be the length of the procedure. Secondary outcomes will include amount of dilation achieved, ease of procedure, participant's assessment of discomfort before mifepristone or dilators, discomfort during the abortion procedure, acceptability to participants, and acceptability to staff.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
50
Inclusion Criteria
  • Women 18-50 years of age undergoing surgical termination of pregnancy
  • English or Spanish speaking
  • Gestational age between 15 and 18 weeks gestation on day of abortion (inclusive), by ultrasound dating
  • Eligible for a dilation and evacuation abortion with local anesthesia and sedation
  • Ultrasound for dating purposes done within the last two weeks
Exclusion Criteria
  • Intrauterine infection
  • Fetal demise
  • Ruptured membranes
  • Multiple gestation
  • Uterine anomaly or significant distortion of the uterus with fibroids
  • BMI greater than 45
  • Inability to place osmotic dilators
  • Active substance abuse or intoxication
  • Adrenal failure, chronic corticosteroid use, anticoagulant usage
  • Severe cervicitis, until treated and resolved
  • Prior Cesarean section

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Osmotic dilatorsosmotic dilatorsPlaced 20-24 hours prior to procedure
Mifepristone + misoprostolMifepristoneMifepristone 200 mg PO given 20-24 hours prior to procedure, misoprostol 400 mcg given 2 hours prior to procedure
Primary Outcome Measures
NameTimeMethod
Length of ProcedureSubjects will be followed from the administration of mifepristone/misoprostol or laminaria, until the end of their procedure, a total of two days.

Interval from speculum insertion to speculum removal

Secondary Outcome Measures
NameTimeMethod
Cervical Dilation AchievedAt time of abortion

Cervical dilation at start of procedure

Subject Discomfort Before the AbortionSubjects will be followed from the administration of mifepristone/misoprostol, or laminaria, until the end of their procedure, a total of two days.

Pain was subjectively described by the subjects as : None, Mild, Moderate, Severe

Pain Medication (Fentanyl) During the AbortionSubjects will be followed from the administration of mifepristone/misoprostol, or laminaria, until the end of their procedure, a total of two days.

Amount of pain medication used during the procedure: reported as micrograms of fentanyl

Operative TimeSubjects will be followed from the administration of mifepristone/misoprostol, or laminaria, until the end of their procedure, a total of two days.

Interval from initiation of vacuum aspiration to speculum removal

Acceptability to PatientAfter procedure completion

Patient was asked whether they would choose to be in the same group again if they had a similar procedure again. The number of participants whose response was "yes" is being reported.

Difficulty of ProcedureAfter completion of procedure

Outcome measure is the number and percentage of participants where the provider rated the procedure as "difficult or very difficult". Provider assessment of difficulty of procedure categories were: "very easy", "easy", "moderate", "difficult", or "very difficult."

Pain Medication (Midazolam) During the AbortionSubjects will be followed from the administration of mifepristone/misoprostol, or laminaria, until the end of their procedure, a total of two days.

Amount of pain medication used during the procedure: reported as milligrams of midazolam

Trial Locations

Locations (1)

Boston University

🇺🇸

Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath